Week In Review: WuXi PharmaTech Co., Ltd. Announces $3.3 Billion Go-Private Offer

May 2, 2015 -- WuXi PharmaTech, China's largest CRO/CMO, received a $3.3 billion privatization offer from Dr. Ge Li, the company's CEO/founder, and Ally Bridge Group; China Cord Blood announced a take-private offer of $512 million from Golden Meditech Holdings, its largest shareholder; Shenzhen Hepalink Pharma signed a framework agreement to acquire greater China rights for a novel BET inhibitor from Resverlogix of Canada; Scanadu, a California diagnostic device maker, raised $35 million in a Series B round led by China investors Fosun International and Tencent Holdings; WuXi PharmaTech began construction of its $150 million biologics manufacturing facility in Wuxi city; Green Cross of South Korea will build a new cell therapy manufacturing facility in China's Guizhou province; and TaiGen Biotechnology of Taiwan started a China clinical trial of burixafor, a novel drug being tested as a chemotherapy sensitizer.

Help employers find you! Check out all the jobs and post your resume.